What medication is used to keep PDA?

Keeping a Lifeline Open: Alprostadil in Newborns with Heart Defects

When a newborn enters the world with a critical congenital heart defect—such as a cyanotic lesion or an interrupted aortic arch—a tiny blood vessel called the ductus arteriosus can be a lifeline. This vessel, which normally closes shortly after birth, allows blood to bypass the lungs and maintain circulation until surgical correction is possible. In these fragile infants, keeping it open is crucial.

Alprostadil, a synthetic form of prostaglandin E1 (PGE1), is the medication used to maintain patency of the ductus arteriosus. It acts by relaxing the smooth muscle in the vessel wall, preventing premature closure. This temporary measure ensures adequate oxygen delivery to the body while the medical team prepares for definitive intervention, such as surgery.

Alprostadil is particularly effective in premature infants, whose ductal tissue may be more responsive to prostaglandins. However, its use requires careful monitoring—side effects like apnea, fever, or hypotension can occur, especially in term or near-term babies. Dosing must be precise, typically delivered via continuous intravenous infusion, and treatment is usually short-term, bridging the gap between diagnosis and correction.

The window of opportunity is narrow. Administering alprostadil promptly can stabilize a critically ill newborn, turning a potentially fatal condition into a manageable one. Pediatric cardiologists and neonatologists rely on this therapy daily, especially in the first hours and days of life when timing is everything.

While alprostadil doesn’t cure the underlying defect, it buys precious time—time for diagnostics, stabilization, and planning. In the delicate world of neonatal cardiology, it remains a cornerstone therapy, quietly saving lives one heartbeat at a time.